
Human papillomavirus type 16 Protein E7 85-93, GTLGIVCPI
Description
About Human papillomavirus type 16 Protein E7 85-93, GTLGIVCPI
The Human Papillomavirus (HPV) 16 Protein E7 Peptide (IEDB: 22738) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Protein E7 Peptide, H-GTLGIVCPI-OH (Uniprot: P03129 aa: 85-93) from JPT is produced under strict quality control and quality management.
Human papillomavirus type 16 Protein E7 85-93, GTLGIVCPI - Specifications
- Peptide sequence: H-GTLGIVCPI-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human papillomavirus type 16 Protein E7 85-93, GTLGIVCPI
References:
Read References with JPT’s Antigen Peptides
Human papillomavirus type 16 Protein E7 85-93, GTLGIVCPI has been described in:
Definition of the HLA-A2 restricted peptides recognized by human CD8+ effector T cells by flow-assisted sorting of the CD8+ CD45RA+ CD28- T cell subpopulation., Clin Exp Immunol, 2003 (PMID: 12519392)
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides., J Immunol, 1995 (PMID: 7538538)
A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients., Int J Mol Sci, 2023 (PMID: 36768214)
Documentation
Documentation for Human papillomavirus type 16 Protein E7 85-93, GTLGIVCPI
Properties
Properties of Human papillomavirus type 16 Protein E7 85-93, GTLGIVCPI
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Human Papillomavirus (HPV) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human papillomavirus type 16 Protein E7 85-93, GTLGIVCPI
Information | Values |
---|---|
Sequence: | H-GTLGIVCPI-OH |
Specifications: | 9mer peptide as TFA salt |